What is Hypertrophic cardiomyopathy?
Hypertrophic cardiomyopathy (HCM) is a common genetically inherited heart disease and represents an important cause of cardiovascular morbidity and mortality in patients of all ages. HCM is characterized by left ventricular hypertrophy unexplained by secondary causes and a nondilated left ventricle with preserved or increased ejection fraction. It is commonly asymmetrical, with the most severe hypertrophy involving the basal interventricular septum.
Although the onset of symptoms can occur at any age, typically, symptoms begin between the ages of 20 and 40. Symptoms vary but result from left ventricular outflow tract (LVOT) obstruction, diastolic dysfunction, myocardial ischemia, and supraventricular and ventricular arrhythmias. The histological features of HCM include myocyte hypertrophy and disarray, as well as interstitial fibrosis. Hypertrophy is also frequently associated with left ventricular diastolic dysfunction. In the majority of patients, HCM has a relatively benign course. However, HCM is also an important cause of sudden cardiac death, particularly in adolescents and young adults.
Mutations in over a dozen genes encoding sarcomere-associated proteins cause HCM. MYH7 and MYBPC3, encoding the β-myosin heavy chain and myosin-binding protein C, respectively, are the two most common genes involved, together accounting for ~50% of the HCM families. The causal genes remain to be identified in many HCM patients. Mutations in genes responsible for storage diseases also cause a phenotype resembling HCM (genocopy or phenocopy).
The main classifications of HCM are obstructive and nonobstructive HCM. Obstructive HCM can be described as sub-aortic and mid-ventricular based on the site of obstruction. Systolic opposition of the mitral leaflet against the septum produces sub-aortic obstruction, while and muscular opposition in the mid-ventricular area produces midventricular obstruction
What is the Hypertrophic cardiomyopathy Treatment Market?
It covers the details of conventional and current medical therapies, and diagnoses are available in the Hypertrophic Cardiomyopathy (HCM) market to treat the condition. It also provides country-wise treatment guidelines and algorithms across the United States, Europe, and Japan. The DelveInsight Hypertrophic Cardiomyopathy (HCM) market report gives a thorough understanding of HCM symptoms by including disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides HCM symptoms of treatment algorithms and treatment guidelines for HCM symptoms in the US, Europe, and Japan.
What is the Hypertrophic cardiomyopathy Market?
DelveInsight’s ‘Hypertrophic Cardiomyopathy (HCM)–Market Insights, Epidemiology, and Market Forecast—2030’ report deliver an in-depth understanding of the Hypertrophic Cardiomyopathy (HCM), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Original Source:- Hypertrophic Cardiomyopathy Market Report
